A novel rapamycin analog is highly selective for mTORC1 in vivo

A novel rapamycin analog is highly selective for mTORC1 in vivo

Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Katherine H. Schreiber, Sebastian I. Arriola Apelo, Deyang Yu, Jacqueline A. Brinkman, Michael C. Velarde, Faizan A. Syed, Chen-Yu Liao, Emma L. Baar, Kathryn A. Carbajal, Dawn S. Sherman, Denise Ortiz, Regina Brunauer, Shany E. Yang, Stelios T. Tzannis, Brian K. Kennedy, Dudley W. Lamming
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/62fe1b728b0148059e306c8857df6c69
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/62fe1b728b0148059e306c8857df6c69

Ejemplares similares